Heron Therapeutics v. Qilu Pharmaceutical: 13-Patent Aprepitant Emulsion Dispute Settles in Delaware
Heron Therapeutics filed suit against Qilu Pharmaceutical in the Delaware District Court, asserting 13 patents covering its injectable aprepitant emulsion formulation used to prevent chemotherapy-induced nausea. The case resolved by settlement after 230 days, with all claims dismissed without prejudice and no costs awarded to either party.
Thirteen-Patent Aprepitant Fortress Ends in Settlement, Not Adjudication
On 21 March 2025, Heron Therapeutics, Inc. filed a patent infringement action against Qilu Pharmaceutical Co., Ltd. in the United States District Court for the District of Delaware, asserting thirteen patents directed at injectable aprepitant emulsion formulations — specifically a 32 mg/4.4 mL (7.2 mg/mL) intravenous product used as an NK1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting. The asserted portfolio spans multiple application lineages, covering formulation composition, manufacturing methods, and related therapeutic uses.
The case closed on 6 November 2025 when the parties entered a Stipulation and Order of Dismissal, dismissing all claims, counterclaims, affirmative defenses, and demands without prejudice and without costs to any party. The Delaware District Court expressly retained jurisdiction to adjudicate any issues arising from the settlement, suggesting a structured settlement agreement — likely involving licensing terms, launch conditions, or an agreed market-entry date — governs the commercial relationship going forward.
The 230-day resolution is consistent with early-stage pharmaceutical ANDA-type disputes that reach commercial resolution before substantive claim construction or invalidity briefing. The ‘without prejudice’ dismissal and court-retained jurisdiction are notable: Heron preserves the right to reassert claims if settlement terms are breached, while the specific terms of the underlying agreement remain confidential. What drove resolution — whether Qilu agreed to a licensing arrangement, delayed launch, or exit from the U.S. market — is unknown from the public record.
Filing to Case Settled in 230 days
230-day duration — typical for ANDA-adjacent pharmaceutical disputes that settle before trial
Case settled: what a without-prejudice dismissal means for both parties
Stipulated dismissal without prejudice — not a final merits ruling
A dismissal without prejudice pursuant to a stipulated order means no court has ruled on patent validity, infringement, or enforceability. The parties agreed to end this specific action on negotiated terms. Heron retains the right to refile infringement claims against Qilu — including on the same 13 patents — if the settlement terms are violated or a new triggering event occurs. The court’s retained jurisdiction is a standard mechanism to enforce the settlement agreement itself.
No merits adjudicationHeron preserves enforcement rights across its full 13-patent portfolio
Because dismissal was without prejudice, Heron’s 13 asserted patents emerge from this action with no court-determined validity or enforceability findings. The patent fortress — spanning formulation composition through manufacturing method claims — remains fully intact and re-assertable. Settlement with court-retained jurisdiction typically signals Heron secured commercially meaningful protections, likely governing if and when Qilu may commercially launch its aprepitant emulsion in the United States.
Portfolio intact, rights preservedQilu avoids adverse validity finding but faces ongoing launch constraints
Qilu obtained no ruling that any of Heron’s 13 patents are invalid or not infringed — a missed opportunity to clear the path via litigation. The settlement’s confidential terms likely govern Qilu’s commercial entry timeline for the U.S. injectable aprepitant market. Without a published license or consent judgment, competitors cannot rely on this outcome as precedent. Qilu’s ability to commercialise its 7.2 mg/mL intravenous aprepitant product in the United States remains subject to the undisclosed agreement.
Launch conditions undisclosedThirteen-patent block on IV aprepitant remains the market reality for third parties
For any other generic or biosimilar company targeting the injectable aprepitant emulsion space, this settlement provides no clearance. Heron’s 13-patent portfolio — covering distinct formulation and method claims across multiple application families — was never challenged to a merits ruling. The portfolio’s breadth and the court-retained jurisdiction signal Heron is actively managing its IP estate. Any third-party entrant must independently assess FTO across all 13 asserted patents plus any continuation applications that may issue.
Portfolio risk unresolved for third partiesFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Heron Therapeutics, Inc. | Company | Specialty pharmaceutical company — holder of 13 aprepitant emulsion formulation patentsSearch in Eureka ↗ |
| Defendant | Qilu Pharmaceutical Co., Ltd. | Company | Chinese generic pharmaceutical manufacturer seeking U.S. market entry for injectable aprepitantSearch in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Heron Therapeutics, Inc.Search in Eureka ↗ |
| Defendant counsel | Ian Scott | Attorney | Counsel for Qilu Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Kenneth Laurence Dorsney | Attorney | Counsel for Qilu Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant law firm | Morris James LLP | Law Firm | Representing Qilu Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Presiding judge | Judge William C. Bryson | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal order’s phrasing — ‘all claims, counterclaims, affirmative defenses, and demands’ — signals a comprehensive resolution covering not only Heron’s infringement assertions but also any invalidity or unenforceability defences Qilu had raised or preserved. The explicit ‘without costs’ language and the court’s retained jurisdiction are consistent with a negotiated commercial settlement rather than a unilateral withdrawal, suggesting both parties reached binding commercial terms that required judicial enforcement backstop.
US10624850B2 and 12 further patents — injectable aprepitant emulsion formulations
The thirteen asserted patents cover Heron’s proprietary injectable aprepitant emulsion platform — a water-insoluble NK1 receptor antagonist reformulated as a stable intravenous emulsion to replace the previous Cremophor-based oral formulation. The patents span multiple application families filed across application numbers from US15/012532 (earliest) through US18/418030 (most recent), indicating a sustained prosecution strategy building claims from foundational composition through manufacturing, dosing, and method-of-use coverage. The commercial product at issue is a 32 mg/4.4 mL (7.2 mg/mL) IV emulsion indicated for prevention of chemotherapy-induced nausea and vomiting.
Strategically, this portfolio exemplifies a ‘patent thicket’ approach common in injectable specialty pharma: overlapping composition, formulation, and method claims filed across multiple continuation families create a layered enforcement barrier. For competitors, the diversity of claim types — covering both the emulsion composition and the therapeutic methods — means that engineering around any single patent family may be insufficient. The portfolio’s breadth also raises the likelihood that pending continuations not yet issued could extend enforceable exclusivity beyond the current 13-patent set, particularly as the most recently filed applications (US18/408486 and US18/418030) suggest active prosecution is ongoing.
Should you run an FTO against Heron’s aprepitant emulsion patent portfolio?
Any company developing, manufacturing, or seeking regulatory approval for an injectable aprepitant emulsion product — including 7.2 mg/mL IV formulations — should conduct a comprehensive freedom-to-operate analysis against all 13 asserted patents and related pending applications. This is not limited to generic pharmaceutical manufacturers: contract development and manufacturing organisations (CDMOs), formulators developing alternative NK1 antagonist emulsions, and oncology drug delivery companies working on IV antiemetic platforms all face potential exposure. The without-prejudice settlement means no claim has been narrowed or invalidated by judicial ruling.
PatSnap Eureka’s FTO Search Agent can map all 13 asserted patent numbers — plus continuation family members — against your specific formulation parameters, excipient choices, and manufacturing process steps. Eureka identifies claim-level overlap risk, flags pending applications in the same prosecution families, and surfaces prior art that could support an IPR petition if a specific claim poses a blocking risk. For an injectable pharmaceutical product with 13 active patent barriers, an automated claim-by-claim FTO analysis is the most efficient way to prioritise design-around investment.
Run a freedom-to-operate analysis on US10624850B2 to assess your product’s exposure
Run FTO in Eureka →Similar injectable pharmaceutical patent cases in the Delaware District Court
Related ANDA-adjacent infringement actions over injectable drug formulations litigated in the Delaware District Court, including NK1 antagonist and oncology supportive care IP disputes.
What this case signals for the injectable pharmaceutical IP landscape
A 13-patent settlement in Delaware’s specialist pharmaceutical docket carries clear implications for generic entry strategy and formulation IP management.
Large patent portfolios on single drug products deter early merits litigation
Asserting 13 patents on a single injectable formulation creates a litigation cost and complexity threshold that often drives settlement before claim construction. Generic entrants face the risk that even if they invalidate several patents, surviving claims may still block launch. Companies targeting the aprepitant emulsion space should model the cost of challenging all 13 patents — not just the closest prior art claims.
Without-prejudice dismissal with retained jurisdiction is a structured settlement signal
When a Delaware district court retains jurisdiction post-dismissal, the underlying settlement almost certainly contains performance-based triggers — consent-to-launch dates, royalty obligations, or breach-reinstatement clauses. This structure means the dispute is commercially resolved but not legally extinguished. Monitoring Qilu’s eventual U.S. product launch date will indicate the settlement’s effective terms.
Heron v Qilu — key questions answered
Heron Therapeutics asserted 13 U.S. patents in Case No. 1:25-cv-00357, including US10624850B2, US11744800B2, US11173118B2, US9808465B2, US10953018B2, US11878074B2, US9974793B2, US9974794B2, US12115254B2, US10500208B2, US12115255B2, US9561229B2, and US9974742B2. All cover aspects of Heron’s injectable aprepitant emulsion formulation platform for intravenous antiemetic use.
The case settled after 230 days and was dismissed without prejudice by stipulated order on 6 November 2025. Dismissal without prejudice means no court ruled on patent validity or infringement — Heron retains the right to refile claims against Qilu on the same patents if the settlement terms are breached. The Delaware court retained jurisdiction to enforce the settlement agreement.
The product at issue is an injectable emulsion for intravenous use containing 32 mg/4.4 mL (7.2 mg/mL) of aprepitant — an NK1 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting. Qilu Pharmaceutical was seeking to market this generic formulation in the United States, which Heron alleged would infringe its 13-patent portfolio.
No. Because the case was dismissed without prejudice pursuant to settlement — with no claim construction, summary judgment, or trial — no court made any finding on the validity, enforceability, or infringement of the 13 asserted patents. The portfolio remains unchallenged by judicial ruling, and third parties cannot rely on this outcome for clearance purposes.
Heron Therapeutics was represented by Morris, Nichols, Arsht & Tunnell LLP, with attorney Jeremy A. Tigan listed as counsel. Qilu Pharmaceutical was represented by Morris James LLP, with Ian Scott and Kenneth Laurence Dorsney listed as defence counsel. The case was assigned to Judge William C. Bryson sitting by designation in the District of Delaware.
PatSnap Eureka searches patents and litigation data to answer instantly.